Cover Image
close this bookHIV Vaccine Development: From Basic Research to Human Trials (UNAIDS, 1996, 33 p.)
View the document(introduction...)
View the documentIntroduction
View the documentHuman clinical trials
View the documentConclusions
View the documentAcknowledgements
View the documentReferences

References

1. Merson MH: Slowing the spread of HIV: agenda for the 1990s. Science 1993, 260:1266 - 1268.

2. Esparza J, Osmanov S, Heyward WL: HIV preventive vaccines: progress to date. Drugs 1995, 50:792 - 804.

3. Bolognesi DP: The dilemma of developing and testing AIDS vaccines. In Global Challenge of AIDS. Edited by Shiokawa Y, Nakamura T. Tokyo: Kodansha/Karger; 1995:147 - 157.

4. Hilleman M: Vaccinology, Immunology, and comparative pathogenesis of measles in the quest for a preventative against AIDS. AIDS Res Hum Retroviruses 1994, 10:3 - 12.

5. Levy JA: HIV research: a need to focus on the right target. Lancet 1995, 345:1619 - 1621.

6. Levy J-P: The problem of a vaccine against AIDS (in French). Medicine/Science (Paris) 1995, 11:407 - 419.

7. Montelaro RC, Bolognesi DP: Vaccines against retroviruses. In The Retroviridae, Vol 4. Edited by Levy JA. New York: Plenum Publishing Corporation; 1995.

8. Moore JP: Back to primary school. Nature 1995, 376: 115.

9. Moore J, Anderson R: The WHO and why of HIV vaccine trials. Nature 1994, 372: 313 - 314.

10. Paul WE: Reexamining AIDS research priorities. Science 1995, 267:633 - 636.

11. Schwartz DH: Potential pitfalls on the road to an effective HIV vaccine. Immunology Today 1994, 15:54 - 57.

12. Osborn JE: The rocky road to an AIDS vaccine. J Acquir Immune Defic Syndr Human Retrovirol 1995, 9:26 - 29.

13. World Health Organization: Scientific and public health rationale for HIV vaccine efficacy trials. AIDS 1995, 9:WHO1 - WHO4.

14. Mascola JR, McNeil JG, Burke DS: AIDS vaccines: are we ready for human efficacy trials? JAMA 1994, 272:488 - 489.

15. Duliege A-M, Sinangil F, Walker C, Dekker C, Steimer K: Status and future of Biocine® HIV-1 rgp120SF2 subunit vaccines: the experience of the Biocine Company. In Retroviruses of Human AIDS and Related Animal Diseases, 9e Colloque des ‘Cent Gardes’. Edited by Girard M, Valette L. Marnes-La-Coquette, Paris: Fondation Marcel Meux; 1994:301 - 307.

16. Francis DP: Laboratory empiricism, clinical design, and social value: the rough road toward vaccine development. In Vaccine Design: The subunit and Adjuvant Approach. Edited by Powell MF, Newman MJ. New York: Plenum Press; 1995:135 - 139.

17. Plotkin SA, Duliege A-M, Esparza J, et al.: Round table: should the candidate HIV vaccines be tested for efficacy in phase III trials? In Retroviruses of Human AIDS and Related Animal Diseases, 9e Colloque des ‘Cent Gardes’. Edited by Girard M, Valette L. Marnes-La-Coquette, Paris: Fondation Marcel Meux; 1994:321 - 333.

18. Pantaleo G, Graziosi C, Fauci AS: The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993, 328:327 - 335.

19. Koup RA, Ho DD: Shutting down HIV. Nature 1994, 370:416.

20. Koup RA, Safrit JT, Cao Y, et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68:4650 - 4655.

21. Pantaleo G, Demarest JF, Soudeyns H, et al.: Major expansion of CD8+ T cells with a predominant Vusage during the primary immune response to HIV. Nature 1994, 370:463 - 467.

22. Moore JP, Cao Y, Ho DD, Koup RA: Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994, 68:5142 - 5155.

23. Easterbrook PJ: Non-progression in HIV infection. AIDS 1994, 8:1179 - 1182.

24. Buchbinder SP, Katz MH, Hessol NA, O’Malley PM, Holmberg SD: Long-term HIV-1 infection without immunological progression. AIDS 1994, 8:1123 - 1128.

25. Cao Y, Quin L, Zhang L, Safrit J, Ho DD: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995, 332:201 - 208.

26. Wong MT, Warren RQ, Anderson SA, et al.: Longitudinal analysis of the humoral response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-infected subjects. J Infect Dis 1993, 168:1523 - 1527.

27. Huang Y, Zhang L, Ho DD: Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection. J Virol 1995, 69:93 - 100.

28. Pantaleo G, Menzo S, Vaccarezza M, et al.: Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995, 332:209 - 216.

29. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995, 332:228 - 232.

30. Michael NL, Chang G, D’Arcy LA, et al.: Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. J Virol 1995, 69:4228 - 4236.

31. Baltimore D: Lessons from people with nonprogressive HIV infection. N Engl J Med 1995, 332:259 - 260.

32. Mellors JW, Kingsley LA, Rinaldo CR, et al.: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Int Med 1995, 122:573 - 579.

33. Chakrabarti L, Cummont M-C, Montagnier L, Hurtrel B: Variable course of primary simian immunodeficiency virus infection in lymph nodes: relation to disease progression. J Virol 1994, 68:6634 - 6642.

34. Hirsch VM, Goldstein S, Hynes NA, et al.: Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine. J Infect Dis 1994, 170:51 - 59.

35. Hirsch VM, Dapolito G, Johnson PR, et al.: Induction of AIDS by simian immunodeficiency virus from an african green monkey: species-specific variation in pathogenicity correlates with the extent of in vivo replication. J Virol 1995, 69:955 - 967.

36. Rowe P: Resistance to HIV infection. Lancet 1993, 341:624.

37. Bevan MJ, Braciale TJ: Why can’t cytotoxic T cells handle HIV? Proc Natl Acad Sci USA 1995, 92:5765 - 5767.

38. Ferbas J, Kaplan AH, Hausner MA, et al.: Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity. J Infect Dis 1995, 172:329 - 339.

39. Moss PAH, Rowland-Jones SL, Frodsham PM, et al.: Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. Proc Natl Acad Sci USA 1995, 92:5773 - 5777.

40. Koenig S, Conley AJ, Brewah YA, et al.: Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nature Medicine 1995, 1:330 - 336.

41. Mathieson BJ: CTL to HIV-1: surrogates or sirens. Nature Medicine 1995, 1:304 - 305.

42. Emini EA, Schleif WA, Numberg JM, et al.: Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992, 355:728 - 730.

43. Prince AM, Reesink H, Pascal D, et al.: Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses 1991, 7:971 - 973.

44. Putkonen P, Thornstensson B, Ghavamzadeh L, et al.: Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature 1991, 352:436 - 438.

45. Myers G, Korber BTM, Smith RF, Berzofsky JA, Pavlakis GN: Human Retroviruses and AIDS. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 1993.

46. Osmanov S, Heyward WL, Esparza J: The World Health Organization network for HIV isolation and characterization: summary of a pilot study. AIDS Res Hum Retroviruses 1994, 10:1325 - 1326.

47. WHO Network for HIV Isolation and Characterization: HIV type 1 variation in World Health Organization-sponsored vaccine evaluation sites: genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains. AIDS Res Hum Retroviruses 1994, 10: 1327 - 1343.

48. Moore JP, McCutchan FE, Poon S-W, Mascola J, Liu J, Cao Y, Ho DD: Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol 1994, 68:8350 - 8364.

49. Trkola A, Pomales AP, Yuan H, et al.: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995, 69:6609 - 6617.

50. Moore JP, Cao Y, Qin L, Korber B, Ho DD: Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996, 70:427-444.

51. Kostrikis LG, Cao Y, Ngai H, Moore JP, Ho DD: Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 1996, 70:445-458.

52. Nkengansong JN, Peeters M, Ndumbe P, et al.: Cross-neutralizing antibodies to HIV-1ANT70 and HIV-1IIIB in sera of African and Belgian HIV-1-infected individuals. AIDS 1994, 8:1089 - 1096.

53. Mascola JR, Louwagie J, McCutchan FE, et al.: Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J Infect Dis 1994, 169:48 - 54.

54. j Morfeldt-Manson L, Albert J, Biberfeld G, Karlsson A, Lindman K, Feny: Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986, ii:660 - 662.

55. Tersmette M, De Goede REY, Winkel I, et al: Differential syncytium-inducing capacity of human immunodeficiency virus isolates: Frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988, 62:2026 - 2032.

56. Feny, Morfeldt-Manson L, Chiodi F, et al: Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol 1988, 62:4414 - 4419.

57. De Wolf F, Hogervorst E, Goudsmit J, et al.: Syncytium-inducing and non-syncytium inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. AIDS Res Hum Retroviruses 1994, 10:1387 - 1400.

58. Rubsamen-Waigmann H, Von Briesen H, Holmes H, et al.: Standard conditions of virus isolation reveal biological variability if HIV type 1 in different regions of the world. AIDS Res Hum Retroviruses 1994, 10:1401 - 1408.

59. Zhu T, Mo H, Wang N, et al.: Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993, 261:1179 - 1181.

60. Bolognesi D: Humoral immune responses to primary HIV isolates: implications for vaccine development. In Retroviruses of Human AIDS and Related Animal Diseases, 9e Colloque des ‘Cent Gardes’. Edited by Girard M, Valette L. Marnes-La-Coquette, Paris: Fondation Marcel Meux; 1994:285 - 291.

61. Hanson CV: Measuring vaccine-induced HIV neutralization: report of a workshop. AIDS Res Hum Retroviruses 1994, 10:645 - 648.

62. Matthews TJ: Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res Hum Retroviruses 1994, 10:631 - 632.

63. Bou-Habib DC, Roderiquez G, Oravecz T, Berman PW, Lusso P, Norcross MA: Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994, 68:6006 - 6013.

64. Broder CC, Earl PL, Long D, Abedon ST, Moss B, Doms RW: Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc Natl Acad Sci USA 1994, 91:11699 - 11703.

65. Earl PL, Broder CC, Long D, et al.: Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 1994, 68:3015 - 3026.

66. Moore JP, Ho DD: HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 1995, 9(suppl A):S117 - S136.

67. Moore JP, Cao Y, Qing L, et al.: Primary isolates of human immundodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995, 69:101 - 109.

68. Sattentau QJ, Moore JP: Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med 1995, 182:185 - 196.

69. Sullivan N, Sun Y, Li J, Hofmann W, Sodroski J: Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol 1995, 69:4413 - 4422.

70. Sawyer LSW, Terri Wrin M, Crawford-Miksza L, et al.: Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell line in which the virus is propagated. J Virol 1994, 68:1342 - 1349.

71. Stott J, Almond N: Assessing animal models of AIDS. Nature Medicine 1995, 1:295 - 297.

72. Stott EJ: Anti-cell antibody in macaques (letter). Nature 192, 353:393.

73. Arthur LO, Bess JW, Urban RG, et al.: Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency viruses. J Virol 1995, 69:3117 - 3124.

74. Putkonen P, Nilsson C, Hild K, Benthin R, Cranage M, Aubertin AM, Biberfeld G: Whole inactivated SIV vaccines grown on human cells fails to protect against homologous SIV grown on simian cells. J Med Primatol 1993, 22:100 - 103.

75. de Vries P, Heeney JL, Boes J, et al.: Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines. Vaccine 1994, 12:1443 - 1452.

76. Giavedoni LD, Planelles V, Haigwood NL, et al.: Immune responses of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol 1993, 67:577 - 583.

77. Israel ZR, Edmonson PF, Maul DH, et al.: Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol 1994, 68:1843 - 1853.

78. Siegel F, Kurth R, Norley S: Neither whole inactivated virus immunogen nor passive immunoglobulin transfer protects against SIVAGM infection in the african green monkey natural host. J Acquir Immune Defic Syndr Human Retrovirol 1995, 8:217 - 226.

79. Daniel MD, Mazzara GP, simon MA, et al.: High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection. AIDS Res Hum Retroviruses 1994, 10:839 - 851.

80. Hu S-L, Abrams K, Barber GN, et al.: Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992, 255:456 - 459.

81. Hu S-L, Polacino P, Stallard V, et al.: Transmembrane protein and core antigens in protecting against SIV infection. In Vaccines 95, Cold Spring Harbor Laboratory Press. 1995:167 - 173.

82. Hu S-l, Polacino P, Stallard V, et al.: Is subunit envelope antigen our best bet for an AIDS vaccine? In Retroviruses of Human AIDS and Related Animal Diseases, 9e Colloque des ‘Cent Gardes’. Edited by Girard M, Valette L. Marnes-La-Coquette, Paris: Fondation Marcel Meux; 1994:275 - 281.

83. Desrosiers RC: HIV with multiple gene deletions as a live attenuated vaccine for AIDS. AIDS Res Hum Retroviruses 1992, 8:411 - 421.

84. World Health Organization Working Group: Feasibility of developing live attenuated HIV vaccines: conclusions and recommendations. AIDS 1994, 10:221 - 222.

85. Clements JE, Montelaro RC, Zink MC, et al.: Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol 1995, 69:2737 - 2744.

86. Almond N, Kent K, Cranage M, Rud E, Clarke B, Stott EJ: Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 1995, 345:1342 - 1344.

87. Ruprecht RM, Baba TW, Greene MF; Almond N, Cranage M, Stott J: Attenuated vaccines for AIDS? Lancet 1995, 346:177 - 179.

88. Baba TW, Jeong YS, Penninck D, Bronson R, Greene MF, Ruprecht RM: Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995, 267:1820 - 1825.

89. Beale J: An attenuated vaccine for AIDS? Lancet 1995, 345:1318 - 1319.

90. Marthas ML, Van Rompay KKA, Otsyula M, et al.: Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques. J Virol 1995, 69:4198 - 4205.

91. Putkonen P, Bjng E, erblom L, et al.: Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 Iscom vaccine. J Acquir Immune Defic Syndr 1994, 7:551 - 559.

92. Franchini G, Robert-Guroff M, Tartaglia J, et al.: Highly attenuated HIV 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques. AIDS Res Hum Retroviruses 1995, 11:909 - 920.

93. Abimiku AG, Franchini G, Tartaglia J, et al.: HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nature Medicine 1995, 1:321 - 329.

94. Travers K, Mboup S, Marlink R, et al.: Natural protection against HIV-1 infection provided by HIV-2. Science 1995, 268:1612 - 1615.

95. Berman PW, Murthy KK, Wrin T, et al.: Protection of MN-rgp 120 immunized chimpanzees from heterologous infection with a primary isolate of HIV-1. J Infect Dis 1996, 173:52 - 59.

96. Girard M, Meignier B, Barrinoussi, et al.: Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol 1995, 69:6239 - 6248.

97. Bruck C, Thiriart C, Fabry L, et al.: HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine 1994, 12:1141 - 1148.

98. Fultz PN, Wei Q, Yue L, Barrinoussi F, Girard M: HIV-1 dynamics after superinfection of chimpanzees with strains from two different clades. Annual Meeting of the Laboratory of Tumor Cell Biology. Bethesda, MD, August 1995, Abstract # 283. AIDS Res Hum Retroviruses 1995, 11 (suppl 1):S135.

99. Esparza J, Osmanov S: The development and evaluation of HIV vaccines. Curr Opin Infect Dis 1993, 6:218 - 229.

100. Walker MC, Fast PE: Clinical trials of experimental AIDS vaccines. AIDS 1994, 8(suppl 1):S213 - S236.

101. Fast P: Phase I and II trials of candidate HIV-1 vaccines: current status and future directions. In Retroviruses of Human AIDS and Related Animal Diseases, 9e Colloque des ‘Cent Gardes’. Edited by Girard M, Valette L. Marnes-La-Coquette, Paris: Fondation Marcel Meux; 1994:293 - 299.

102. Belshe RB, Bolognesi D, Clements ML, et al.: Studies on HIV-1 vaccines by the AIDS Vaccine Evaluation Group (AVEG). Annual Meeting of the Laboratory of Tumor Cell Biology. Bethesda, MD, August 1995, Abstract # 296. AIDS Res Hum Retroviruses 1995, 11 (suppl 1):S135.

103. Belshe RB, Graham BS, Keefer MC, et al.: Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994, 272:475 - 480.

104. Kahn JO, Sinangil F, Baenziger J, et al.: Clinical and immunological responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J Infect Dis 1994, 170:1288 - 1291.

105. Belshe RB, Clements ML, Dolin R, et al.: Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J Infect Dis 1993, 168:1387 - 1395.

106. Gorse GJ, Rogers JH, Perry JE, et al.: HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. Vaccine 1995, 13:209 - 214.

107. Gorse GJ, Schwartz DH, Graham BS, et al.: HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immunol 1994, 98:178 - 184.

108. Gorse GJ. Phase I/II trials of preventive HIV vaccine candidates. Dose and schedule: summary. AIDS Res Hum Retroviruses1994, 10(suppl 2):S141 - S143.

109. Gorse GJ, Frey SE, Patel G, Newman FK, Belshe RB, NIAID AIDS Vaccine Clinical Trials Network: Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. Vaccine 1994, 12: 912 - 918.

110. Graham BS, Gorse GJ, Schwartz DH, et al.: Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. J Infect Dis 1994, 170:782 - 786.

111. McElrath MJ, Corey L, Berger D, et al.: Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting. J Infect Dis 1994, 169:41 - 47.

112. Plotkin SA, Cadoz M, Meignier B, et al.: The safety and use of canarypox vectored vaccines. Dev Biol Stand 1995, 84:165 - 170.

113. Egan MA, Pavlat WA, Tartaglia J, et al.: Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector(ALVAC) carrying the HIV-1MN env gene. J Infect Dis 1995; 171:1623 - 1627.

114. Pialoux G, Excler J-L, Rivi Y, et al.: A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res Hum Retroviruses 1995, 11:373 - 381.

115. Excler J-L, Salmon D, Sicard D, et al.: Safety and immunogenicity of a live recombinant canarypox virus vaccine expressing gp120/gag/protease boosted by a p24-V3 peptide. Annual Meeting of the Laboratory of Tumor Cell Biology. Bethesda, MD, August 1995, Abstract # 295. AIDS Res Hum Retroviruses 1995, 11 (supl 1):S138.

116. O’Hagan DT, McGee JP, Wang CY, Potts B, Koff WC: The UBI multicomponent HIV® vaccine rgp120SF2 subunit vaccines: the advantages of controlled release microparticles. In Retroviruses of Human AIDS and Related Animal Diseases, 8e Colloque des ‘Cent Gardes’. Edited by Girard M, Valette L. Marnes-La-Coquette, Paris: Fondation Marcel Meux; 1993:309 - 313.

117. Rubinstein A, Goldstein H, Pettoello-Mantovani M, et al.: Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers. AIDS 1995, 9:243 - 251.

118. Cohen J: Thailand weighs AIDS vaccine tests. Science 1995, 270:904 - 907.

119. Belshe RB, Bolognesi DP, Clements ML, et al.: HIV infection in vaccinated volunteers (letter). JAMA 1994, 272:431.

120. Kahn JO, Steimer KS, Baenziger J, et al.: Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial. J Infect Dis 1995, 171:1343 - 1347.

121. Esparza J: Development of WHO-sponsored sites for HIV vaccine evaluation. AIDS Res Hum Retroviruses 1993, 9(suppl 1):S133 - S134.

122. Esparza J, Osmanov S, Kallings LO, Wigzell H: Planning for HIV vaccine trials: the World Health Organization perspective. AIDS 1991, 5(suppl 2):S159 - S163.

123. Esparza J, Osmanov S, Clements ML, Heymann D: Preparation for efficacy trials of preventive HIV candidate vaccines: the role of the World Health Organization. In Retroviruses of Human AIDS and Related Animal Diseases, 7e Colloque des ‘Cent Gardes’. Edited by Girard M, Valette L. Marnes-La-Coquette, Paris: Fondation Marcel Meux; 1992:217 - 222.

124. Hoff R: Preparation for HIV vaccine trials: moving from baseline studies to efficacy trials. AIDS Res Hum Retroviruses 1994, 10(suppl 2):S191 - S193.

125. Heyward WL, Osmanov S, Saba J, et al.: Preparation for Phase III HIV vaccine efficacy trials: methods for the determination of HIV incidence. AIDS 1994, 8:1285 - 1291.

126. Chesney MA, Lurie P, Coates TJ: Strategies for addressing the social and behavioural challenges of prophylactic HIV vaccine trials. J Acquir Immune Defic Syndr Human Retrovirol 1995, 9:30 - 35.

127. Jenkins RA, Temoshok LR, Virochsiri K: Incentives and disincentives in prophylactic HIV vaccine research. J Acquir Immune Defic Syndr Human Retrovirol 1995, 9:36 - 42.

128. Temoshok LR: Behavioural research contributions to planning and conducting HIV vaccine efficacy trials. AIDS Res Hum Retroviruses 1994, 10(suppl 2):S277 - S280.

129. Wasi C, Herring B, Raktham S, et al.: Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide-binding enzyme immunoassay and heteroduplex mobility assay: evidence of increasing infection with HIV-1 subtype E. AIDS 1995, 9:843 - 849.

130. Kalish ML, Baldwin A, Raktham S, et al.: The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: implications for HIV vaccine trials. AIDS 1995, 9:851 - 857.

131. Esparza J, Osmanov S, Heyward WL, Piot P: Ethical aspects of trials of candidate vaccines against the human immunodeficiency virus (HIV). In Proceedings of the 4th International Seminar on Immunizations in Africa. Yamoussoukro, Cd’Ivoire, March 1994: 330 - 331.

132. Burke DS: Human trials of experimental HIV vaccines. AIDS 1995, 9(suppl A):S171 - S180.

133. Johnston MI, Noe JS, Killen JY: Recent advances in AIDS vaccine research and development. AIDS Res Hum Retroviruses 1994, 10(suppl 2):S317 - S323.

134. Haynes BF: Scientific and social issues of Human Immunonodeficiency Virus vaccine development. Science 1993, 260:1279 - 1286.